Acetaminophen shows no direct effects on developing brain organoids in autism research

A new study examining acetaminophen's effects on developing brain tissue has found no evidence that the drug damages neural structures during a critical window of fetal development. Researchers exposed cortical organoids—miniature brain-like structures grown in the laboratory—to acetaminophen at concentrations meant to model late first-trimester exposure, then measured what changed.

Nothing did, by most measures. The organoids maintained their size. Their internal architecture remained intact. The cells stayed viable. The density of synaptic connections—the points where neurons communicate—showed no difference. The balance between mature neurons and the progenitor cells that generate them stayed the same. Even when the researchers pushed the dose to its highest level, the effects were minimal: some shifts in gene expression appeared, but they did not persist when the team checked again at a later time point.

These laboratory findings matter because acetaminophen is the most widely used over-the-counter pain reliever and fever reducer in pregnancy. For decades it was considered safe. Then, beginning around 2014, a series of epidemiological studies raised questions about whether prenatal exposure might increase the risk of autism or attention-deficit/hyperactivity disorder. The concern was serious enough that it prompted warnings and shifted clinical practice in some places. Parents and physicians faced genuine uncertainty.

Large-scale population studies have since reassured: women who took acetaminophen during pregnancy do not appear to have higher rates of children with autism. But reassurance from population data alone leaves a gap. It tells you what happened, not why. It does not explain the biological mechanism—or rule out that one exists. This new work approaches the question from the other direction. If acetaminophen truly damages developing brains, there should be a way to see it happen in controlled conditions. The researchers designed an experiment to look.

What they found was absence. No structural damage. No loss of cells. No disruption to the basic wiring plan. The transcriptional noise at the highest dose—changes in which genes were turned on or off—faded away, suggesting it was a transient response rather than lasting harm. The picture that emerges is of a drug that, at least in this model system and at these exposure levels, does not interfere with the fundamental processes of early brain development.

This does not close the book on acetaminophen and neurodevelopment. Laboratory organoids are simplified systems; they lack the full complexity of a living fetus, the presence of other tissues, the maternal immune system, the placenta. They model a specific stage and a specific exposure scenario. Real pregnancy is messier and longer. But the study does something important: it tests a specific hypothesis about a specific mechanism and finds no evidence for it. That alignment—between what large populations show and what cells show in a dish—is the kind of convergence that builds confidence.

The finding arrives as autism research continues to expand in multiple directions. This week alone, other teams published work on how genetic mutations disrupt brain circuitry, how organoid networks self-organize, and how behavioral development differs between children at high and low genetic risk. The field is learning that autism emerges from many sources, involves many brain systems, and unfolds across development in ways that are still being mapped. Acetaminophen, it appears, is not one of those sources.